Clinical trials recruiting for Melanoma Metastatic

Phase breakdown

Drugs and treatments being studied

Self-screener

Recruiting trials

• A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
  NCT07076550 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
  NCT06889610 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study
  NCT07050940 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma.
  NCT07686835 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
  NCT06889766 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)
  NCT06586593 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can Predict Response to Immunotherapy.
  NCT06784778 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma
  NCT06767306 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic Melanoma
  NCT06880198 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
  NCT06783270 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma
  NCT07750067 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Melanoma Metastatic often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Melanoma Metastatic trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.